Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.42 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 4/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018330 | 0.92 | FFAR4 (0.38) | FFAR4NPY2RGRM5CNR1PDE5A | |
| SCHEMBL25823605 | 0.92 | FFAR4 (0.38) | FFAR4NPY2RGRM5CNR1PDE5A | |
| SCHEMBL25819403 | 0.87 | FFAR4 (0.42) | FFAR4NPY2RGRM5CNR1PRMT5 | |
| SCHEMBL25935224 | 0.84 | FFAR4 (0.44) | FFAR4NPY2RGRM5CNR1TRPV1 | |
| SCHEMBL25935029 | 0.83 | FFAR4 (0.46) | FFAR4KDM4E | |
| SCHEMBL25819356 | 0.82 | CYP11B2 (0.42) | FFAR4PRMT5 | |
| SCHEMBL25819461 | 0.82 | FFAR4 (0.42) | FFAR4NPY2RCNR1KDM4ECNR2 | |
| SCHEMBL25819203 | 0.82 | FFAR4 (0.61) | FFAR4 | |
| SCHEMBL25935221 | 0.82 | FFAR4 (0.41) | FFAR4NPY2RGRM5 | |
| SCHEMBL25935316 | 0.81 | FFAR4 (0.38) | FFAR4CNR1KDM4ECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | FFAR4 4754/4885NPY2R 4852/4885GRM5 3397/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | FFAR4 4733/4885NPY2R 4818/4885GRM5 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.